口服普萘洛尔对血管瘤患儿体格发育的近期影响

中国口腔颌面外科杂志 ›› 2016, Vol. 14 ›› Issue (6): 510-513.

口服普萘洛尔对血管瘤患儿体格发育的近期影响

董建勇^{1, 2*, *}, 李凯^{3*, *}, 岳琳琳¹, 李荣慧¹, 黄莹莹¹, 刘少华²

1.山东大学口腔医学院,山东济南 250012;
2.山东大学齐鲁医院口腔颌面外科, 山东济南 250012;
3.天津市口腔医院（南开大学口腔医院）口腔颌面外科,天津 300041

收稿日期:2016-01-26 修回日期:2016-04-10 出版日期:2016-11-20 发布日期:2016-12-05
通讯作者: 刘少华,E-mail:lshabccba@126.com
作者简介:董建勇（1988-）,男,硕士,E-mail:djysdu@126.com; 李凯（1990-）,男,硕士,住院医师,E-mail:likai0925@outlook.com。 *并列第一作者

Influence of oral propranolol on growth and development of children with infantile hemangiomas

DONG Jian-yong^{1, 2}, LI Kai³, YUE Lin-lin¹, LI Rong-hui¹, HUANG Ying-ying¹, LIU Shao-hua²

1.School of Stomatology, Shandong University. Jinan 250012;
2. Department of Oral and Maxillofacial Surgery, Qilu Hospital , Shandong University. Jinan 250012, Shandong Province;
3. Department of Oral and Maxillofacial Surgery of Tianjin Stomatological Hospital. Tianjin 300041, China

Received:2016-01-26 Revised:2016-04-10 Online:2016-11-20 Published:2016-12-05

摘要/Abstract

摘要： 目的研究长期口服普萘洛尔对血管瘤患儿体格发育的影响。方法收集2010年1月—2014年8月就诊于山东大学齐鲁医院的血管瘤患儿资料,手术切除者为手术组,口服普萘洛尔治疗者为普萘洛尔组。于2014年12月通过电话、信件等方式收集患儿体格发育指标,以2组患儿体重、身高、坐高、头围、胸围、上臂围、体质指数、体重/身高、胸围/身高、坐高/身高等 10 项指标作为评价儿童体格发育标准,将获得的不同年龄和性别的2组指标数据分别与《中国七岁以下儿童生长参照标准》和WHO儿童正常生长指标进行比较,并以年龄、性别和居住地作为协变量,采用SPSS 18.0 软件包对2组患儿各项生长指标作协方差分析。结果 118例患儿（普萘洛尔组92例,手术组26例）纳入研究,经统计学分析,10项指标中仅身高和胸围有统计学差异（P=0.038<0.05,P=0.041<0.05）,普萘洛尔组患儿身高、胸围均值分别较手术组低11.11 cm和3.25 cm。结论长期口服普萘洛尔可能延缓血管瘤患儿的身高和胸围发育。

关键词: 普萘洛尔, 血管瘤, 体格发育

Abstract: PURPOSE: To investigate the effect of oral propranolol on growth and development of children with infantile hemangioma(IH). METHODS: Children with IHs during Jan. 2010 and Aug. 2014 treated with surgery or oral propranolol in Qilu Hospital were recruited. The children were divided into surgery group and propranolol group. Phone calls and letters were used for investigation in December 2014. Ten indicators including weight, height (length), sitting height, head circumstance, chest circumstance, upper limber circumstance, body weight index (BMI), weight/height (length), chest/height and sitting height/height were selected to evaluate their growth and development levels. The data were analyzed based on Chinese Growth Reference Standards under 7 and WHO Child Growth Standards, and tested by age, sex and place of residence as covariates, covariance analysis. RESULTS: One hundred and eighteen cases (92 for propranolol and 26 for surgery) were included. Covariance analysis indicated significant differences of height and chest circumstance among 10 indicators between surgery and propranolol groups(P=0.038<0.05, P=0.041<0.05), and the height and chest of the propranolol were lower than those of surgery (11.11 cm and 3.25 cm) the average differences were 11.11 cm and 3.25 cm. CONCLUSIONS: Long-term oral propranolol may lead to hypoevolutism of height and chest circumference in children with IH.

Key words: Propranolol, Hemangiomas, Physical development

中图分类号:

R739.8

董建勇, 李凯, 岳琳琳, 李荣慧, 黄莹莹, 刘少华. 口服普萘洛尔对血管瘤患儿体格发育的近期影响[J]. 中国口腔颌面外科杂志, 2016, 14(6): 510-513.

DONG Jian-yong, LI Kai, YUE Lin-lin, LI Rong-hui, HUANG Ying-ying, LIU Shao-hua. Influence of oral propranolol on growth and development of children with infantile hemangiomas[J]. China J Oral Maxillofac Surg, 2016, 14(6): 510-513.

参考文献

[1] Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants [J]. Arch Dis Child-Fetal Neonatal Ed, 2015, 100(1): F85-91.
[2] Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA [J]. Pediatr Dermatol, 2005, 22(5): 383-406.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[4] 郑家伟, 张凌, 陈正岗. 普萘洛尔治疗婴幼儿血管瘤专家共识 [J]. 中国口腔颌面外科杂志, 2013, 11(2): 161-164.
[5] Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference [J]. Pediatrics, 2013, 131(1): 128-140.
[6] Cissoko H, Jonville-Béra AP, Swortfiguer D, et al. Neonatal outcome after exposure to beta adrenergic blockers late in pregnancy [J]. Arch Pediatrie, 2005, 12(5): 543-547.
[7] Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients [J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[8] 王卫平. 儿科学[M]. 第8版. 北京: 人民卫生出版社, 2013: 8-15.
[9] World Health Organization. The WHO child growth evaluation software [DB/OL]. (2015-1-7)[2016-01-26]. http://www.who.int/childgrowth/software/en/.
[10] 中华人民共和国国家卫生和计划生育委员会. 卫生部妇社司关于印发《中国7岁以下儿童生长发育参照标准》的通知 [Z].
[11] 中华人民共和国国家卫生和计划生育委员会. 中国7岁以下儿童生长参照标准[EB/OL]. (2015-01-27)[2016-01-26]. http://www.nhfpc.gov.cn/fys/s3585/200906/a81e441c2f754cd2a1e2527b43eb376e.shtml.
[12] World Health Organization. The WHO child growth standards[DB/OL]. (2015-01-07)[2016-01-26]. http://www.who.int/childgrowth/standards/en/.
[13] 九市儿童体格发育调查协作组, 首都儿科研究所. 2005年中国九市七岁以下儿童体格发育调查[J]. 中华儿科杂志, 2007, 45(8): 609-614.
[14] Stiles J, Amaya C, Pham R, et al. Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis [J]. Exp Ther Med, 2012, 4(4): 594-604.
[15] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J]. 中华心血管病杂志, 2009, 37(3): 195-209.